Voyager reports Q2 2026 results, sets Q4 milestones for two Alzheimer's programs

Voyager Therapeutics reported second quarter 2026 results on August 6, 2026, highlighting progress on its two tau-targeted Alzheimer's disease programs. CEO Alfred Sandrock said the company views tau as a critical disease-modifying target in Alzheimer's disease and believes recent third-party data support that view.¹

For VY7523, an anti-tau antibody, Voyager said it expects tau PET imaging efficacy data in the fourth quarter of 2026 from an ongoing multiple ascending dose trial in Alzheimer's disease patients.¹

For VY1706, a tau silencing gene therapy, the FDA cleared Voyager's IND application, allowing the company to begin a clinical trial in adults with early Alzheimer's disease in the U.S., with dosing expected to start in the fourth quarter of 2026.¹ Separately, Health Canada cleared the corresponding Clinical Trial Application in July, allowing Canadian sites to join the study.¹ At the AAIC 2026 meeting, Voyager presented preclinical data showing VY1706 was well tolerated in a 6-month GLP toxicology study in non-human primates and produced sustained tau protein reduction of up to 75% in key Alzheimer's disease brain regions after a single intravenous dose.¹

On the Friedreich's ataxia program partnered with Neurocrine Biosciences, Neurocrine has said it plans to start a clinical trial of NBIB-'223 in the second half of 2026, contingent on FDA IND clearance.¹

Looking further out, Voyager listed potential initial acute safety data for VY1706 in early 2027, pending enrollment, and potential initial biomarker-based data in the second half of 2027.¹

On finances, cash, cash equivalents, and marketable securities totaled $148.8 million as of June 30, 2026, which the company said, together with anticipated collaboration reimbursements and interest income, should fund operations into 2028.¹